ArticleAsia-Pacific journal of clinical oncology2021
Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study.
Article in Asia-Pacific journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Prognosis of Pregnancy-Associated Breast Cancer: A Systematic Review of Contemporary Observational Studies.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Trimester of diagnosis affects tumor characteristics and survival in breast cancer during pregnancy: first results from the STURGATE collaboration.NPJ breast cancer · 2026Article
- Multidisciplinary management of pregnancy-associated breast cancer: a clinical pharmacy perspective on chemotherapy and perinatal outcomes.Frontiers in oncology · 2026Article
- Giant triple negative pregnancy-associated breast cancer (PABC) in a young woman: From diagnosis to therapy step by step: A case report.Radiology case reports · 2025Article
- Retrospective study of 35 cases of breast cancer associated with pregnancy at the Monastir Maternity and Neonatology Center.The Pan African medical journal · 2025Article
- Measurable progression of giant cell tumour of bone associated with pregnancy - A tertiary sarcoma centre analysis.Journal of clinical orthopaedics and trauma · 2024Article
- Impact of Pregnancy on Breast Cancer Features and Prognosis.Current oncology (Toronto, Ont.) · 2024Article
- Systematic Review of Survival Outcomes of Pregnancy-Associated Breast Cancer in Asian Countries.The Malaysian journal of medical sciences : MJMS · 2024Review
- Survival probabilities and prognostic factors of pregnancy-associated breast cancer in Malaysian women.Obstetrics & gynecology science · 2024Article
- Gestational Breast Cancer - a Review of Outcomes, Pathophysiology, and Model Systems.Journal of mammary gland biology and neoplasia · 2023Review
- Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge.Diagnostics (Basel, Switzerland) · 2023Review
- Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study.Asia-Pacific journal of clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe aimed to clarify tumor features and prognosis of pregnancy-associated breast cancer (PABC) among Chinese women.
methodsPABC was defined as breast cancer diagnosed during pregnancy or within a year after delivery. Patients with PABC were selected from breast cancer cases of women ≤45 years treated at our institution between December 2012 and December 2017, and one non-PABC control was matched for stage, age, and year of diagnosis for each case.
resultsForty-one women with PABC were identified (22 diagnosed during pregnancy and 19 within 1 year of delivery). There were significantly more progesterone receptor (PR)- and triple-negative tumors in the PABC (56.1% and 24.4%, respectively) than in the non-PABC group (31.7% and 4.9%, respectively) (P = .045 and .026, respectively). Human epidermal growth factor receptor 2 positivity was the same in both groups (31.7%). Median disease-free survival (DFS) was 29.0 months (95% confidence interval [CI], 6.5-51.5 months) in the PABC and 40.9 months (95% CI, 22.8-58.8 months) in the non-PABC group (P = .167). Median overall survival (OS) was 82.8 months in the PABC (95% CI, 39.3-126.5 months) versus 80.1 months (95% CI, 56.7-103.6 months) in the non-PABC group (P = .131).
conclusionHistological features were similar in both groups, except that PR- and triple-negative tumors were more frequent in the PABC group. Survival analyses show similar OS for patients with PABC and non-PABC. DFS tended to be shorter in the PABC group; however, this difference was not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.